These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 33911188)

  • 1. Reversal of hypertriglyceridemia in diabetic BTBR ob/ob mice does not prevent nephropathy.
    Attie AD; Schueler KM; Keller MP; Mitok KA; Simonett SP; Hudkins KL; Mehrotra K; Graham MJ; Lee RG; Alpers CE
    Lab Invest; 2021 Jul; 101(7):935-941. PubMed ID: 33911188
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reversibility of structural and functional damage in a model of advanced diabetic nephropathy.
    Pichaiwong W; Hudkins KL; Wietecha T; Nguyen TQ; Tachaudomdach C; Li W; Askari B; Kobayashi T; O'Brien KD; Pippin JW; Shankland SJ; Alpers CE
    J Am Soc Nephrol; 2013 Jun; 24(7):1088-102. PubMed ID: 23641056
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Beneficial effect on podocyte number in experimental diabetic nephropathy resulting from combined atrasentan and RAAS inhibition therapy.
    Hudkins KL; Wietecha TA; Steegh F; Alpers CE
    Am J Physiol Renal Physiol; 2020 May; 318(5):F1295-F1305. PubMed ID: 32249614
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of CP-900691, a novel peroxisome proliferator-activated receptor α, agonist on diabetic nephropathy in the BTBR ob/ob mouse.
    Askari B; Wietecha T; Hudkins KL; Fox EJ; O'Brien KD; Kim J; Nguyen TQ; Alpers CE
    Lab Invest; 2014 Aug; 94(8):851-62. PubMed ID: 24955894
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regression of diabetic nephropathy by treatment with empagliflozin in BTBR ob/ob mice.
    Hudkins KL; Li X; Holland AL; Swaminathan S; Alpers CE
    Nephrol Dial Transplant; 2022 Apr; 37(5):847-859. PubMed ID: 34865099
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Grem2 mediates podocyte apoptosis in high glucose milieu.
    Wen H; Kumar V; Mishra A; Song S; Aslam R; Hussain A; Wang H; Zhou X; He X; Wu G; Luo H; Lan X; Malhotra A; Singhal PC
    Biochimie; 2019 May; 160():113-121. PubMed ID: 30831151
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacological PAR-1 inhibition reduces blood glucose levels but does not improve kidney function in experimental type 2 diabetic nephropathy.
    Waasdorp M; Florquin S; Duitman J; Spek CA
    FASEB J; 2019 Oct; 33(10):10966-10972. PubMed ID: 31287960
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The SGLT2 inhibitor empagliflozin ameliorates early features of diabetic nephropathy in BTBR ob/ob type 2 diabetic mice with and without hypertension.
    Gembardt F; Bartaun C; Jarzebska N; Mayoux E; Todorov VT; Hohenstein B; Hugo C
    Am J Physiol Renal Physiol; 2014 Aug; 307(3):F317-25. PubMed ID: 24944269
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BTBR Ob/Ob mutant mice model progressive diabetic nephropathy.
    Hudkins KL; Pichaiwong W; Wietecha T; Kowalewska J; Banas MC; Spencer MW; Mühlfeld A; Koelling M; Pippin JW; Shankland SJ; Askari B; Rabaglia ME; Keller MP; Attie AD; Alpers CE
    J Am Soc Nephrol; 2010 Sep; 21(9):1533-42. PubMed ID: 20634301
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impaired Podocyte Autophagy Exacerbates Proteinuria in Diabetic Nephropathy.
    Tagawa A; Yasuda M; Kume S; Yamahara K; Nakazawa J; Chin-Kanasaki M; Araki H; Araki S; Koya D; Asanuma K; Kim EH; Haneda M; Kajiwara N; Hayashi K; Ohashi H; Ugi S; Maegawa H; Uzu T
    Diabetes; 2016 Mar; 65(3):755-67. PubMed ID: 26384385
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antisense oligonucleotide inhibition of apolipoprotein C-III reduces plasma triglycerides in rodents, nonhuman primates, and humans.
    Graham MJ; Lee RG; Bell TA; Fu W; Mullick AE; Alexander VJ; Singleton W; Viney N; Geary R; Su J; Baker BF; Burkey J; Crooke ST; Crooke RM
    Circ Res; 2013 May; 112(11):1479-90. PubMed ID: 23542898
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term expression of glomerular genes in diabetic nephropathy.
    Chittka D; Banas B; Lennartz L; Putz FJ; Eidenschink K; Beck S; Stempfl T; Moehle C; Reichelt-Wurm S; Banas MC
    Nephrol Dial Transplant; 2018 Sep; 33(9):1533-1544. PubMed ID: 29340699
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Emerging role of podocyte autophagy in the progression of diabetic nephropathy.
    Yasuda-Yamahara M; Kume S; Tagawa A; Maegawa H; Uzu T
    Autophagy; 2015; 11(12):2385-6. PubMed ID: 26565953
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oral anserine supplementation does not attenuate type-2 diabetes or diabetic nephropathy in BTBR ob/ob mice.
    Everaert I; Van der Stede T; Stautemas J; Hanssens M; van Aanhold C; Baelde H; Vanhaecke L; Derave W
    Amino Acids; 2021 Aug; 53(8):1269-1277. PubMed ID: 34264387
    [TBL] [Abstract][Full Text] [Related]  

  • 15. APOC-III Antisense Oligonucleotides: A New Option for the Treatment of Hypertriglyceridemia.
    Schmitz J; Gouni-Berthold I
    Curr Med Chem; 2018; 25(13):1567-1576. PubMed ID: 28595549
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The compositional abnormalities of lipoproteins in diabetic renal failure.
    Attman PO; Knight-Gibson C; Tavella M; Samuelsson O; Alaupovic P
    Nephrol Dial Transplant; 1998 Nov; 13(11):2833-41. PubMed ID: 9829487
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of hepatic insulin expression on lipid metabolism in diabetic mice.
    Qu S; Zhang T; Dong HH
    J Diabetes; 2016 May; 8(3):314-23. PubMed ID: 25851734
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dysregulation of low-density lipoprotein receptor contributes to podocyte injuries in diabetic nephropathy.
    Zhang Y; Ma KL; Liu J; Wu Y; Hu ZB; Liu L; Liu BC
    Am J Physiol Endocrinol Metab; 2015 Jun; 308(12):E1140-8. PubMed ID: 25921580
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Absence of miR-146a in Podocytes Increases Risk of Diabetic Glomerulopathy via Up-regulation of ErbB4 and Notch-1.
    Lee HW; Khan SQ; Khaliqdina S; Altintas MM; Grahammer F; Zhao JL; Koh KH; Tardi NJ; Faridi MH; Geraghty T; Cimbaluk DJ; Susztak K; Moita LF; Baltimore D; Tharaux PL; Huber TB; Kretzler M; Bitzer M; Reiser J; Gupta V
    J Biol Chem; 2017 Jan; 292(2):732-747. PubMed ID: 27913625
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Podocyte-specific chemokine (C-C motif) receptor 2 overexpression mediates diabetic renal injury in mice.
    You H; Gao T; Raup-Konsavage WM; Cooper TK; Bronson SK; Reeves WB; Awad AS
    Kidney Int; 2017 Mar; 91(3):671-682. PubMed ID: 27914709
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.